Prostatic Hyperplasia

Tadalafil (IC-351) is a PDE5 inhibitor with an IC₅₀ value of 1.8 nM.

RS 17053 hydrochloride is a selective α1A-adrenoceptor antagonist. RS 17053 hydrochloride binds to MrcA/MecA A-class penicillin-binding proteins, inhibits peptidoglycan biosynthesis, and binds to α1A and α1B/α1D-adrenoceptors. RS 17053 hydrochloride disrupts bacterial membranes, causing depolarization, ATP depletion, protein leakage, ROS accumulation, and upregulation of stress response genes. RS 17053 hydrochloride exerts bactericidal activity against Gram-positive/Gram-negative pathogens. RS 17053 hydrochloride can be used for research on bacterial infections and benign prostatic hyperplasia.

Tripotassium hydroxycitrate is an orally active, multi-target, multi-bioactive organic acid. Tripotassium hydroxycitrate activates Nrf2 and its downstream molecule GPX4, increases glutathione levels, and thereby inhibits ferroptosis. Tripotassium hydroxycitrate activates the Nrf2/Keap1 and ACLY/NF-κB signaling pathways, upregulates the activities of antioxidant enzymes such as superoxide dismutase, reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improves pulmonary vascular and right ventricular remodeling. Tripotassium hydroxycitrate activates both the AMPK and mTORC1/S6K pathways, triggers the unfolded protein response, arrests the cancer cell cycle, and induces DNA fragmentation.

Quercetin 5-O-β-D-glucopyranoside is a glycosylated flavonoid metabolite and flavonoid compound. Quercetin 5-O-β-D-glucopyranoside can be produced by microbial transformation of Quercetin (HY-18085) via Mucor hiemalis. Quercetin 5-O-β-D-glucopyranoside can be used in studies related to benign prostatic hyperplasia.

Paraprost (Glutamic acid-alanine-glycine mixture) is an amino acid mixture composed of L-Glutamic acid (HY-14608), L-Alanine (HY-N0229), and Glycine (HY-Y0966). Paraprost can be used for research on benign prostatic hyperplasia.

RS 17053 free base is a selective α1A-adrenoceptor antagonist. RS 17053 free base binds to MrcA/MecA A-class penicillin-binding proteins, inhibits peptidoglycan biosynthesis, and binds to α1A and α1B/α1D-adrenoceptors. RS 17053 free base disrupts bacterial membranes, causing depolarization, ATP depletion, protein leakage, ROS accumulation, and upregulation of stress response genes. RS 17053 free base exerts bactericidal activity against Gram-positive/Gram-negative pathogens. RS 17053 free base can be used for research on bacterial infections and benign prostatic hyperplasia.

N1-Benzyl-N2-phenylethane-1,2-diamine hydrochloride is a pharmaceutical intermediate that can be used for the synthesis of α1a-adrenergic receptor antagonists.

PDE4/5-IN-1 is a selective phosphodiesterase 4/5 (PDE4/5) dual inhibitor. PDE4/5-IN-1 functionally inhibits PDE5, PDE4B2, and PDE4D2 activity. PDE4/5-IN-1 relaxes isolated rat prostate tissue, enhances nitric oxide-induced relaxation in isolated rat prostate tissue, and reduces alpha-1 adrenoceptor-mediated contractile responses in isolated rat prostate tissue. PDE4/5-IN-1 inhibits proliferation of human hyperplastic prostate cells. PDE4/5-IN-1 can be used for the research of benign prostatic hyperplasia.

(+)-Neoolivil is a natural product that can be found in olives.

α1A/1D-Adrenoceptor antagonist-1 (Compound 15) is a selective α1A/1D-adrenoceptor dual antagonist with IC₅₀ values of 20.26 and 164.9 nM. α1A/1D-Adrenoceptor antagonist-1 shows an IC₅₀ of 1912 nM for α1B-adrenoceptor.α1A/1D-Adrenoceptor antagonist-1 can be used for research of benign prostatic hyperplasia.

Cioteronel is an antiandrogen agent. Cioteronel can be studied in research on androgenetic alopecia.

SNAP-6201 is a selective α_1a adrenoceptor antagonist with a K_i of 0.2 nM. SNAP-6201 exhibits >1400-fold selectivity over α_1b and α_1d adrenoceptors. SNAP-6201 exhibits excellent selectively to inhibit intraurethral pressure (IUP) in the anesthetized dog model. SNAP-6201 can be used for benign prostatic hyperplasia (BPH) research.

SL-89.0591 is a uroselective α1-adrenoceptor antagonist. SL-89.0591 exhibits a more potent blocking effect on urethral receptors than on vascular receptors in anesthetized rabbits, with a lower risk of orthostatic hypotension. SL-89.0591 can be used in research related to benign prostatic hyperplasia.

Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia.

RS 17053 hydrochloride (Standard) is the analytical standard of RS 17053 hydrochloride (HY-101336). This product is intended for research and analytical applications. RS 17053 hydrochloride is a selective α1A-adrenoceptor antagonist. RS 17053 hydrochloride binds to MrcA/MecA A-class penicillin-binding proteins, inhibits peptidoglycan biosynthesis, and binds to α1A and α1B/α1D-adrenoceptors. RS 17053 hydrochloride disrupts bacterial membranes, causing depolarization, ATP depletion, protein leakage, ROS accumulation, and upregulation of stress response genes. RS 17053 hydrochloride exerts bactericidal activity against Gram-positive/Gram-negative pathogens. RS 17053 hydrochloride can be used for research on bacterial infections and benign prostatic hyperplasia.

17β-N,N-Diethylcarbamoyl-4-methyl-4-aza-5α-androstan-3-one (DMAA; 4-MA) is a 5α-reductase inhibitor with a K_i of 5.3 nM. 17β-N,N-Diethylcarbamoyl-4-methyl-4-aza-5α-androstan-3-one inhibits the NADPH-dependent conversion of testosterone to 5α-DHT through competitive binding to the testosterone site, and inhibits both the membrane-bound and solubilized forms of the enzyme. 17β-N,N-Diethylcarbamoyl-4-methyl-4-aza-5α-androstan-3-one partially inhibits prostatic epithelial 3β-hydroxysteroid oxidoreductase and inhibits prostatic cytosolic androgen binding. 17β-N,N-Diethylcarbamoyl-4-methyl-4-aza-5α-androstan-3-one reduces prostatic 5α-dihydrotestosterone and elevates testosterone in vivo, inhibits androgen-dependent prostate and seminal vesicle growth, reduces prostate volume, and inhibits the growth of androgen-dependent prostate tumors. 17β-N,N-Diethylcarbamoyl-4-methyl-4-aza-5α-androstan-3-one can be used in research related to benign prostatic hyperplasia and prostate cancer.

Oxendolone (TSAA-291) is a steroidal antiandrogen with partial agonist properties, exhibiting a K_i value of 1.4 nM for the androgen receptor. Oxendolone exerts tissue-specific androgen receptor activity, induces unique androgen receptor conformational changes, and drives differential cofactor recruitment. Oxendolone is recruited to the androgen receptor in a PIAS1-dependent manner. Oxendolone increases levator ani muscle weight in castrated mice. Oxendolone can be used for research on benign prostatic hyperplasia.

α1A Adrenoceptor antagonist-1 is a selective α1A adrenoceptor antagonist with a human K_i <20 nM. α1A Adrenoceptor antagonist-1 exhibits activity against benign prostatic hyperplasia (BPH) to enable less hindered urine flow. α1A Adrenoceptor antagonist-1 relaxes α1a receptor-enriched urethral smooth muscle tissue without inducing hypotension. α1A Adrenoceptor antagonist-1 can be used for the research of benign prostatic hyperplasia (BPH).